US20080318217A1 - Identification of Gene Associated with Reading Disability and Uses Therefor - Google Patents

Identification of Gene Associated with Reading Disability and Uses Therefor Download PDF

Info

Publication number
US20080318217A1
US20080318217A1 US11/662,325 US66232505A US2008318217A1 US 20080318217 A1 US20080318217 A1 US 20080318217A1 US 66232505 A US66232505 A US 66232505A US 2008318217 A1 US2008318217 A1 US 2008318217A1
Authority
US
United States
Prior art keywords
dcdc2
developing
gene
susceptibility
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/662,325
Other languages
English (en)
Inventor
Jeffrey R. Gruen
Haiying Meng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to US11/662,325 priority Critical patent/US20080318217A1/en
Assigned to YALE UNIVERSITY reassignment YALE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRUEN, JEFFREY R., MENG, HAIYING
Publication of US20080318217A1 publication Critical patent/US20080318217A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • Reading disability also known as developmental dyslexia and also known as dyslexia
  • RD Reading disability
  • developmental dyslexia is one of the most common of the complex neurobehavioral disorders, with prevalence rates ranging from 5 to 17 percent (1). It is characterized by an impairment of reading ability in subjects with normal intelligence and adequate educational opportunities.
  • a range of neuroimaging studies including diffusion tensor and functional magnetic resonance imaging, show that dyslexics have altered brain activation patterns compared to fluent readers when challenged with reading tasks (2). Partial remediation in language processing deficits results in improved reading, ameliorates disrupted function in brain regions associated with phonologic processing, and produces additional compensatory activation in other brain areas (3). These studies also implicate specific brain locations where genes integral to reading and language are expressed, and which likely are altered in RD.
  • the present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD.
  • DCDC2 human gene
  • RD reading disability
  • Forms of the DCDC2 gene that harbor variations that are associated with susceptibility for developing RD or lead to differences in RD are referred to, interchangeably, herein as DCDC2 variants, variant DCDC2 DNA or variant DCDC2 genes.
  • Applicants identified an intronic polymorphic deletion of DCDC2 and alleles of dbSTS ID 808238 within the region that the deletion spans that are in significant disequilibrium with multiple RD traits.
  • DCDC2 in which there is a deletion, such as the intronic polymorphic deletion described herein, and DCDC2 alleles that are associated with RD are examples of DCDC variants.
  • the polymorphic deletion encodes tandem repeats of putative brain-related transcription factor binding sites in intron 2 of DCDC2.
  • RT-PCR data show that DCDC2 localizes to the region of the brain where fluent reading occurs and RNAi studies show that down regulating DCDC2 leads to alteration in neuronal migration, again within the brain regions of interest. Results demonstrate that DCDC2 is a gene correlated with RD.
  • Applicants saturated the region of the genome around JA04, which led to the identification of an intronic polymorphic deletion of DCDC2.
  • Alleles of dbSTS ID 808238 within the region that the deletion spans are in significant disequilibrium with multiple RD traits.
  • RT-PCR data suggest that DCDC2 localizes to the region of the brain where fluent reading occurs and RNAi studies show that down regulating DCDC2 leads to alteration in neuronal migration, again within the brain regions of interest.
  • Applicants' findings support the role of DCDC2 as a gene for harboring variations that lead to differences in RD.
  • the present invention relates to a human gene associated with susceptibility for developing RD, which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD. It also relates to methods for identifying or aiding in identifying individuals at risk for developing RD; methods for diagnosing or aiding in the diagnosis of RD; polynucleotides (e.g., probes, primers) useful in the methods; diagnostic kits containing such probes or primers; antibodies that bind wild type DCDC2 or altered DCDC2 gene product (e.g., protein); methods of treating or aiding in treating an individual at risk for or suffering from RD and compositions, such as pharmaceutical compositions, useful for treating an individual at risk for or suffering from RD; methods for determining appropriate and, preferably, optimal treatment for individuals, including response to educational interventions, curricula, written materials, tutoring, specialized classes and pharmaceuticals related to pharmacogenetics.
  • the methods and compositions of the present invention can be used alone or in combination with other methods and compositions used for such purposes.
  • a method of diagnosing or aiding in the diagnosis of RD of the present invention can be used in conjunction with testing and behavioral assessments presently used for determining if an individual has RD.
  • the methods of the present invention provide DNA (genetic) diagnostic tests useful in assessing RD in individuals, as well as in populations, such as the general population.
  • the present invention provides polynucleotides useful for detecting or aiding in detecting, in a sample, a DCDC2 variant(s).
  • a DCDC2 variant (also referred to as variant DCDC2 DNA or a variant DCDC2 gene) comprises at least one alteration in or difference from wild type DCDC2.
  • the alteration or difference can be any nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5-prime untranslated region, promoter region, enhancer sequence, 3-prime untranslated region or intron that is associated with RD.
  • polymorphisms include, but are not limited to, changes in the amino acid sequence of the proteins encoded by the DCDC2 gene, produce alternative splice products, create truncated products, introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of DCDC2 expression, introduce changes in the tertiary structure of the proteins encoded by DCDC2, introduce changes in the binding affinity or specificity of the proteins expressed by DCDC2 or alter the function of the proteins encoded by DCDC2.
  • the present invention provides methods and compositions useful for identifying or aiding in identifying individuals at risk for developing RD.
  • the methods and compositions of the invention may be used for the treatment of an individual who has (is suffering from) RD or is at risk for developing RD.
  • the invention also encompasses diagnostic kits for detecting, in a sample from an individual, variant DCDC2 DNA, such as a DCDC2 allele that is correlated with RD in humans. Such kits are useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD in an individual.
  • the invention provides an isolated polynucleotide for the detection of a DCDC2 allele that is correlated with RD in humans, the polynucleotide comprising a nucleic acid molecule that specifically detects variant DCDC2 DNA that is correlated with the occurrence of RD in humans.
  • Isolated polynucleotides are useful for detecting, in a sample from an individual, DCDC2 gene variants that are correlated with RD in humans.
  • the isolated polynucleotide is a probe that hybridizes, under highly stringent conditions, to all or a portion of a DCDC2 gene that is correlated with the occurrence of RD in humans (all or a portion of a variant DCDC2 gene).
  • the isolated probe hybridizes, under highly stringent conditions, to all or a portion of a DCDC2 gene that is associated with susceptibility for developing RD in humans but does not hybridize to a DCDC2 gene that is not associated with susceptibility for developing RD in humans.
  • the isolated polynucleotide is a primer that hybridizes, under highly stringent conditions, adjacent, upstream, or downstream to an alteration in a DCDC2 gene that is associated with susceptibility for developing RD in humans.
  • polynucleotides of the present invention can be primers or probes that are useful to identify wild type DCDC2, wild type DCDC2 gene or wild type DCDC2 DNA, as defined herein. Such polynucleotides, for example, recognize or hybridize to all or a portion of wild type DCDC2, wild type DCDC2 gene or wild type DCDC2 DNA.
  • the polynucleotides described herein may be a DNA or RNA molecule.
  • the subject polynucleotide may be single-stranded or double-stranded.
  • Polynucleotide probes and primers of the invention may be from about 5 nucleotides to about 3000 nucleotides. In certain embodiments, the polynucleotide probes and primers of the invention are from about 8 nucleotides to about 500 nucleotides.
  • the polynucleotide probes and primers of the invention are from about 10 to about 250 nucleotides, from about 10 to about 100 nucleotides, from about 10 to about 80 nucleotides, from about 10 to about 50 nucleotides, from about 10 to about 40 nucleotides, from about 10 to about 30 nucleotides, from about 10, 11, 12, 13 or 15 nucleotides to about 20, 21, 22, 23, 24 or 25 nucleotides.
  • the subject polynucleotides may comprise one or more non-natural or modified nucleotides.
  • Non-natural or modified nucleotides include, without limitation, radioactively, fluorescently, or chemically labeled nucleotides, and protein nucleic acids.
  • polynucleotide useful to identify or detect wild type or variant DCDC2 sequences. Based on the information provided herein, one of ordinary skill in the art can design and produce polynucleotide probes and primers using methods known in the art.
  • the polynucleotide primer of the invention hybridizes vicinal to an alteration or difference (nucleotide polymorphism) in a DCDC2 gene that is associated with susceptibility for developing RD in humans.
  • hybridization may occur in such a manner that fewer than 10 nucleotides separate the alteration and the end of the hybridized primer proximal to the alteration.
  • hybridization occurs in such a manner that 1-3 nucleotides separate the alteration and the end of the hybridized primer proximal to the alteration.
  • the polynucleotide primer hybridizes immediately adjacent to the alteration.
  • the polynucleotide primer of the invention hybridizes upstream or downstream from an alteration in the DCDC2 gene that is correlated with the occurrence of RD in humans.
  • hybridization may occur in such a manner that the end of the hybridized primer proximal to the alteration is 10, 25, 50, 100, 250, 1000, 5000, or up to 10,000 nucleotides upstream or downstream from an alteration in the DCDC2 gene.
  • the invention described herein also provides a pair of polynucleotide primers that specifically detect a mutation in the DCDC2 gene that is correlated with the occurrence of RD in humans, wherein the first polynucleotide primer hybridizes to one side of an alteration (e.g., one side of the deletion described herein, such as the 5-prime side) and the second polynucleotide primer hybridizes to the other side of the alteration (e.g., the other side of the deletion described herein, such as the 3 prime side).
  • an alteration e.g., one side of the deletion described herein, such as the 5-prime side
  • the second polynucleotide primer hybridizes to the other side of the alteration (e.g., the other side of the deletion described herein, such as the 3 prime side).
  • a pair of polynucleotide primers that hybridize to a region of DNA that comprises an alteration in the DCDC2 gene that is associated with susceptibility for developing RD in humans may hybridize to the region in such a manner that the ends of the hybridized primers proximal to the alteration are from about 20 to about 10,000 nucleotides apart.
  • variants of the DCDC2 gene that predispose an individual to RD may be detected by the methods and compositions described herein.
  • variant alleles such as those depicted in Supplementary Table 3 may be detected.
  • wild type DCDC2 wild type DCDC2 gene
  • wild type DCDC2 DNA refer to DNA that is not associated with susceptibility for developing RD in humans.
  • the invention provides a method of detecting, in a sample obtained from an individual, a DCDC2 allele that is associated with susceptibility for developing RD in humans.
  • a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under highly stringent conditions, to a DCDC2 allele that is correlated with RD in humans, but does not hybridize to a DCDC2 gene that is not associated with susceptibility for developing RD in humans and (b) determining whether hybridization occurs.
  • the occurrence of hybridization indicates that a DCDC2 gene that is associated with susceptibility for developing RD in humans is present in the sample.
  • the method may comprise: (a) combining the sample with a polynucleotide probe that uses the polymerase chain reaction to amplify, under stringent conditions, a DCDC2 allele that is associated with susceptibility for developing RD in humans, and (b) sequencing the allele, such as by conventional fluorescent tagged dideoxy terminator sequencing, wherein if the allele comprises the sequence of variant DCDC2 DNA, a DCDC2 allele that is associated with susceptibility for developing RD in humans is present in the sample.
  • Samples used in the methods described herein may comprise cells from the eye, epidermis, epithelium, blood, tears, saliva, mucus, urine, stool, sperm, ova, or any other tissues or bodily fluids from which sufficient DNA or RNA can be obtained.
  • cells obtained from a buccal swab are used.
  • the sample should be sufficiently processed to render DNA or RNA present available for assaying in the methods described herein.
  • samples may be processed such that DNA from the sample is available for amplification by DNA polymerases or other enzymes that increase the total DNA content or for hybridization to another polynucleotide.
  • the processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material, or may be purified to specifically isolate DNA or RNA.
  • Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods described herein.
  • Methods for processing samples may include, without limitation, mechanical, chemical, enzymatic, or molecular means of lysing and/or purifying cells and cell lysates.
  • Processing methods may include chromatographic methods such as ion exchange (e.g., cation and anion), size exclusion, affinity, and hydrophobic interaction chromatography.
  • the invention provides a method of detecting, in a sample obtained from an individual, a variant DCDC2 gene that is associated with susceptibility for developing RD in humans, comprising: (a) combining the sample (referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a DCDC2 gene that is associated with susceptibility for developing RD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization in the combination but not in the control indicates that a DCDC2 gene that correlates with RD is present in the sample.
  • the control is the same as the test sample and is treated the same as the test sample, except that the polynucleotide probe is one that does not bind to a DCDC2 gene that is associated with susceptibility for developing RD in humans.
  • the control can be assessed prior to, simultaneous with or subsequent to assessment of the test sample.
  • the control can be a previously established reference or standard.
  • the control is typically the same type of sample as the test sample and is treated the same as the test sample, except that it is combined with a polynucleotide that does not hybridize to a DCDC2 gene that is associated with susceptibility for developing RD in humans.
  • the invention provides a method of detecting, in a sample obtained from an individual, a DCDC2 gene that is associated with susceptibility for developing RD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under highly stringent conditions, to a DCDC2 gene that is correlated with RD in humans, but not to a DCDC2 gene that is not correlated with RD in humans; (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under highly stringent conditions, to a DCDC2 gene that is not correlated with RD in humans, but not to a DCDC2 gene that is correlated with RD in humans; and (c) determining whether hybridization occurs.
  • the occurrence of hybridization in the first portion but not in the second portion indicates that a gene that is correlated with RD is present in the sample.
  • the present invention also relates to a method of detecting, in a sample obtained from an individual, a DCDC2 gene that is associated with susceptibility for developing RD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA (at least one nucleotide) that is present in a DCDC2 gene associated with susceptibility for developing RD but not present in a DCDC2 gene not associated with susceptibility for developing RD and the second polynucleotide primer hybridizes to the other side of DNA (at least one nucleotide) that is present in a DCDC2 gene associated with susceptibility for developing RD, but not present in a DCDC2 gene not associated with susceptibility for developing RD; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the amplified DNA the presence of DNA that is
  • one member of the pair of polynucleotide primers hybridizes to one side of DNA and the other member of the pair hybridizes to the other side of DNA in a DCDC2 gene in which there is a deletion of 2,445 bp, as described herein.
  • the deletion is assigned breakpoints 24,433,346 and 24,435,659 (ENSEMBL database version 33 Sep. 2005).
  • the compound STR is genotyped by sequencing PCR products generated with forward primer (TGTTGAATCCCAGACCACAA) and reverse primer (ATCCCGATGAAATGAAAAGG).
  • the members of the primer pairs each hybridize to specific sequence length variants of Repeat Units 1 through 5 and SNP1 listed in Table 3, thereby distinguishing different DCDC2 variants.
  • a primer pair could be synthesized that specifically and only identifies the presence of allele number 1 in a DNA sample; another primer pair could specifically and only identify allele number 2, and so forth. Any method known in the art for amplifying nucleic acids may be used for the methods described herein.
  • DNA in a sample may be amplified using the polymerase chain reaction, rolling circle amplification, isothermal amplification, strand displacement amplification, multiple strand displacement amplification, multiplex ligation-dependant probe amplification, allele-specific amplification, ligase chain reaction, or by other enzymatic processes.
  • any method known in the art of resolving nucleic acids may be used for the methods described herein, including but not restricted to fluorescence tagged dideoxy sequencing, single base extension, capillary electrophoresis, SNPshot, SNPlex, Invader assay, TaqMan, light-cycle real time quantitative PCR, allele-specific hybridization, restriction fragment length polymorphism, single stranded conformational polymorphisms, denaturing gradient gel electrophoresis, denaturing high-pressure liquid chromatography, oligo-hybridization, tag-arrays, dideoxy method of Sanger sequencing, MALDI-TOF, Pyrosequencing, and reverse transcriptase mediated oligonucleotide extension.
  • a set of three primers is used: one universal primer that is shared between two alleles, and two primers that are each unique for each an allele.
  • the 2,445 bp deletion was genotyped by allele-specific amplification with a combination of three primers in one reaction: a universal or shared forward primer (AGCCTGCCTACCACAGAGAA), a reverse primer for non-deleted chromosomes (GGAACAACCTCACAGAAATGG), and a reverse primer for deleted chromosomes (TGAAACCCCGTCTCTACTGAA).
  • the deletion fusion fragment is 225 bp and the non-deleted fragment is 550 bp.
  • the invention provides methods of identifying or aiding in identifying an individual at risk for developing RD.
  • a method comprises assaying a sample obtained from the individual for the presence of a DCDC2 gene that is associated with susceptibility for developing RD in humans. The presence of a DCDC2 gene associated with susceptibility for developing RD indicates that the individual is at risk for developing RD.
  • a method of identifying or aiding in identifying an individual at risk for developing RD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions such as highly stringent conditions, to a DCDC2 gene that is associated with susceptibility for developing RD in humans, but does not hybridize to a DCDC2 gene that is not associated with susceptibility for developing RD in humans; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing RD.
  • a method of identifying or aiding in identifying an individual at risk for developing RD comprises: (a) obtaining DCDC2 DNA from the individual; (b) sequencing DCDC2 DNA obtained in (a); and (c) determining whether DCDC2 DNA sequenced in (b) comprises DNA (one or more nucleotides) that is present in a DCDC2 gene that is associated with susceptibility for developing RD but is not present in a DCDC2 gene not associated with susceptibility for developing RD.
  • the presence of DNA (one or more nucleotides) that is present in a DCDC2 gene associated with susceptibility for developing RD but is not present in a DCDC2 gene not associated with susceptibility for developing RD indicates that the individual is at risk for developing RD.
  • the invention provides diagnostic kits useful for detecting a DCDC2 gene that is associated with susceptibility for developing RD in a sample from an individual.
  • a diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions such as highly stringent conditions, to a DCDC2 gene that is associated with susceptibility for developing RD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of such a gene in a sample.
  • a diagnostic kit useful for detecting a DCDC2 gene associated with susceptibility for developing RD in humans in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes to one side of DNA (at least one nucleotide) that is present in a DCDC2 gene associated with susceptibility for developing RD but not present in a DCDC2 gene not associated with susceptibility for developing RD; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a DCDC2 gene in a sample.
  • the diagnostic kit may additionally comprise a second polynucleotide primer that hybridizes, under highly stringent conditions, to the other side of DNA (at least one nucleotide) that is present in a DCDC2 gene associated with susceptibility for developing RD, but not present in a DCDC2 gene not associated with susceptibility for developing RD.
  • a second polynucleotide primer that hybridizes, under highly stringent conditions, to the other side of DNA (at least one nucleotide) that is present in a DCDC2 gene associated with susceptibility for developing RD, but not present in a DCDC2 gene not associated with susceptibility for developing RD.
  • the invention provides methods and compositions for treating an individual suffering from RD.
  • a child is assessed, as described herein, and determined to have a variant DCDC2 gene, such as a DCDC2 gene in which there is a deletion (e.g., a 2,445 bp deletion as described herein), which is associated with susceptibility for developing RD, intervention can be more effectively designed.
  • a deletion e.g., a 2,445 bp deletion as described herein
  • intervention can be more effectively designed.
  • a young child shown to have the DCDC2 gene in which the deletion described herein occurs it might be most effective not to stress reading during the first few years of school, but, rather, emphasize other skills and maintain the self esteem of the child.
  • a reading program might be a more effective approach.
  • Another approach to be considered is that of determining whether those with certain alleles, such as those in Supplementary Table 3, respond to presently used drugs, such as phenobarbitol, anti-epileptic drugs and drugs used to treat ADHD (gabaneurgic drugs, such as Ritalin), or drugs designed specifically for the purpose.
  • the methods and compositions described herein for treating a subject suffering from RD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing RD.
  • the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of RD.
  • the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from RD.
  • the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition.
  • Antibodies both monoclonal and polyclonal, that bind, specifically or nonspecifically, to the product of a DCDC2 gene correlated with RD are also the subject of the present invention. These may be shown to be useful for diagnostic purposes whereby the abundance of DCDC2 protein is qualitatively and/or quantitatively assessed in tissues or fluids. Typical applications include, but are not limited to, use of anti-DCDC2 antibodies in a radio-immunoassay test, or ELISA test, or western-blot analysis, among others.
  • FIG. 1 a - 1 c High density SNP QTDT analysis.
  • FIG. 1 a Evidence for transmission disequilibrium for 147 SNPs as ⁇ log 10 P value, and plotted against position in the Ensembl human genomic reference sequence. The locations of 18 genes encoded in this region are provided. The vertical lines on the genes are cSNPs. The location of marker JA04 is shown above the gene map. The longest distance between SNPs was 332 kb located at the centromeric end of the region. The shortest distance was 14 bp in exon 1 of MRS2L.
  • FIG. 1 b ⁇ log 10 P value for 33 SNPs (P ⁇ 0.1) located within DCDC2, MRS2L, and part of GPLD1.
  • FIG. 1 c Further expansion of a 110 kb region within DCDC2. SNPs labeled with an asterisk (*) are associated with RD phenotypes with P ⁇ 0.005.
  • C — 449792 is located within the deleted 2,445 bp in intron 2 of DCDC2 and designated by a triangle ( ⁇ ).
  • the heavy vertical black lines represent exons in DCDC2.
  • the hatched rectangles above exons 1 and 2, and above exons 3 through 5 highlight the coding regions for the DCX doublecortin peptide domains.
  • FIG. 2 a - b LD between pairs of SNPs. Color-coded D′ values for pairs of SNPs are plotted with the GOLD program.
  • FIG. 2 a LD between pairs of SNPs in the 1.5 Mb region. The location of the 147 SNPs in this region are provided in Supplementary Table 1. Gene and haplotype block depictions on the top are relative to marker number and not actual physical distances. Gene and marker locations on the left are proportional to physical distances.
  • FIG. 2 b Triangular excerpt from lower left corner of 2 a with higher resolution of SNPs 19 through 49 covering 180 kb and haplotype blocks A through E in DCDC2. Asterisks (*) indicate SNPs with P ⁇ 0.005.
  • Block A spanned five SNPs (SNPs ID: 21, 22, 23, 24, and 25) and 6.5 kb in intron 8.
  • Block B spanned two SNPs (SNPs ID: 26 and 27) and 23 kb in intron 7 including the single marker peak at SNP 26 with IQ.
  • Block C spanned eight SNPs (SNPs ID: 32, 33, 34, 35, 36, 37, 38, and 39) and 34.2 kb from intron 2 to intron 7, including the highest single marker peak at SNPs 33 with DISC.
  • Block D spanned five SNPs (SNP ID: 42, 43, 44, 45, and 46) and 11.5 kb in intron 2.
  • Block E spanned three SNPs (SNP ID: 47, 49 and 50) and 16 kb in from intron 1 to intron 2 and the 5-prime untranslated region including the single marker peak at SNP 49 with DISC.
  • Block F spanned five SNPs (SNP ID: 68, 69, 70, 71, 72) and 5.4 kb, from MRS2L to GPLD1, including the non-synonymous cSNP in MRS2L, SNP 69.
  • Block G spanned three SNPs (SNP ID: 117, 118, and 119) and 34.4 kb including the single marker peak at SNP 117 with PTP.
  • Block H spanned three SNPs (SNP ID: 128, 129, and 130) and 13.5 kb including the single marker peak at SNP 130 with DISC.
  • FIG. 3 Haplotype-TDT analyses. FBAT results for 12 cognitive phenotypes at haplotype blocks A through H. The locations of the haplotype blocks are presented in FIG. 2 . The markers comprising each haplotype block are described in the legend for FIG. 2 and Supplementary Tables 1 and 2a. Evidence for transmission disequilibrium is plotted as ⁇ log 10 P along the y-axis, for each phenotype represented by tick marks along the x-axis from left to right as: IQ, DISC, PTP, TWR, PWR, WR, PD, OCH, PDL, HCH, OC, and PA.
  • FIG. 5 a - c In utero RNAi against DCDC2.
  • FIG. 5 a Control transfection of a neutral shRNA vector and eGFP shows normal migration after four days. Most neurons have migrated well away from the ventricular surface (Vent) towards the pial surface (Pia).
  • FIG. 5 b Neurons transfected with an shRNA vector directed against DCDC2 migrate abnormally.
  • FIG. 5 c Cumulative probability plot of the migration distances from the ventricular surface of all transfected eGFP+cells shown in panels a and b in the two transfection conditions. Scale bar in panels a and b is 100 ⁇ m.
  • FIG. 6 shows the results of Electrophoresis Mobility Shift Assay on EMSA3 and EMSA4, which show that binding of nuclear proteins to these short doublestranded domains changes their electrophoretic mobility, indicating that it is likely that the short (20 bp) DNA domains bind transcription factors. This suggests that this region is one that can enhance gene expression/is an enhancer.
  • dbSTS ID 808238 polymorphic compound short term repeat
  • Analysis identified 131 putative transcription factor binding sites distributed within the 168 bp of the purine-rich region, including four copies each of PEA3 (AGGAAA) and NF-ATp (AGGAAAG) sites in repeat unit 1 of dsSTS ID 808238. Described herein is a gene, and alleles thereof, associated with susceptibility for developing RD. Results described herein provide evidence for five linkage disequilibrium blocks (designated A to E) that span small clusters of SNPs in DCDC2 ( FIG. 2 b ). A haplotype in each of blocks A, C, D and E (located in DCDC2) and in each of blocks F and G (located centromeric of DCDC2) was associated with compromised performance in several reading tasks in the context of preserved IQ.
  • RES short tandem repeat
  • DYX2 gene and corresponding alleles that create susceptibility for developing RD.
  • Applicants assembled a high-density marker panel of 147 SNPs covering the 1.5 Mb surrounding JA04. This panel was used to assess single-marker and haplotype transmission disequilibrium with quantitative reading performance assessments in RD families. Quantitative expression studies of eight genes included in the panel were correlated with 18 regions of human brain corresponding to the primary functional reading centers.
  • Described herein is a human gene associated with susceptibility for developing RD, which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD. Also described are methods for identifying or aiding in identifying individuals at risk for developing RD; methods for diagnosing or aiding in the diagnosis of RD; polynucleotides (e.g., probes, primers) useful in the methods; diagnostic kits containing such probes or primers; antibodies that bind wild type DCDC2 or altered DCDC2 gene product (e.g., protein); methods of treating or aiding in treating an individual at risk for or suffering from RD and compositions, such as pharmaceutical compositions, useful for treating an individual at risk for or suffering from RD; methods for determining appropriate treatment for individuals, including response to educational interventions, curricula, written materials, tutoring, specialized classes and pharmaceuticals related to pharmacogenetics.
  • polynucleotides e.g., probes, primers
  • the present invention provides two DNA screening tests of the DCDC2 gene sequence that identify genetic susceptibility for developing dyslexia: a deletion assay and a DCDC2 haplotype assay spanning exons 5 through 8. These assays provide two methods of assessing the DCDC2 gene sequence to identify genetic susceptibility for developing dyslexia.
  • a deletion assay and a DCDC2 haplotype assay spanning exons 5 through 8.
  • Example 2 Since the two assays—deletion and haplotype—describe different mutations rarely found together, combining them will identify approximately 30% of dyslexics, as shown in Example 2 (see table entitled “Identification of dyslexics with combined deletion and (AGCTAGA) haplotype assays”).
  • DCDC2 as DYX2 permits further interrogations of the DCDC2 gene sequence for mutations that could cause reading disability. This would involve interrogation of the coding regions of the 10 exons in the public domain (Ref Seq: NM — 016356) and also putative regulatory sequences and unreported exons located within introns, the five-prime untranslated region, and the three-prime untranslated region.
  • Both the deletion assay and haplotype assay, as described herein can be used as a tool to screen for susceptibility to develop reading disability in the general population, as a diagnostic tool for a specific genetic subtype of reading disability, and for genetic counseling within families. These assays can also be used to test and ultimately contribute to decisions about specific forms of remediation.
  • the invention provides isolated and/or recombinant polynucleotides that specifically detect an alteration in a DCDC2 gene that is associated with susceptibility for developing RD (in a variant DCDC2 gene).
  • Polynucleotide probes of the invention hybridize to the alteration of interest, and the flanking sequence, in a specific manner and thus typically have a sequence which is fully or partially complementary to the sequence of the alteration and the flanking region.
  • a variety of alterations in a DCDC2 gene associated with susceptibility for developing RD may be detected by the polynucleotides described herein.
  • any nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5-prime untranslated region, promoter region, enhancer sequence, 3-prime untranslated region or intron that is associated with RD can be detected.
  • polymorphisms include, but are not limited to, changes in the amino acid sequence of the proteins encoded by the DCDC2 gene, produce alternative splice products, create truncated products, introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of DCDC2 expression, introduce changes in the tertiary structure of the proteins encoded by DCDC2, introduce changes in the binding affinity or specificity of the proteins expressed by DCDC2 or alter the function of the proteins encoded by DCDC2.
  • the variation in the DCDC2 gene results in a deletion of 2,445 bp, as described herein. The deletion is assigned breakpoints 24,433,346 and 24,435,659 (Ensembl).
  • the subject polynucleotides are further understood to include polynucleotides that are variants of the polynucleotides described herein, as long as the variant polynucleotides maintain their ability to specifically detect a variation in the DCDC2 gene that is associated with susceptibility for developing RD.
  • Variant polynucleotides may include, for example, sequences that differ by one or more nucleotide substitutions, additions or deletions.
  • the isolated polynucleotide is a probe that hybridizes, under stringent conditions, such as highly stringent conditions, to an alteration in the DCDC2 gene that is associated with susceptibility for developing RD.
  • stringent conditions such as highly stringent conditions
  • hybridization is used in reference to the pairing of complementary nucleic acids.
  • probe refers to a polynucleotide that is capable of hybridizing to another nucleic acid of interest.
  • the polynucleotide may be naturally occurring, as in a purified restriction digest, or it may be produced synthetically, recombinantly or by nucleic acid amplification (e.g., PCR amplification).
  • Nucleic acid hybridization is affected by such conditions as salt concentration, temperature, organic solvents, base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will readily be appreciated by those skilled in the art.
  • Stringent temperature conditions will generally include temperatures in excess of 30° C., or may be in excess of 37° C. or 45° C.
  • Stringent salt conditions will ordinarily be less than 1000 mM, or may be less than 500 mM or 200 mM.
  • SSC sodium chloride/sodium citrate
  • the salt concentration in the wash step can be selected from a low stringency of about 2.0 ⁇ SSC at 50° C. to a high stringency of about 0.2 ⁇ SSC at 50° C.
  • the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22° C., to high stringency conditions at about 65° C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed.
  • the invention provides nucleic acids which hybridize under low stringency conditions of 6.0 ⁇ SSC at room temperature followed by a wash at 2.0 ⁇ SSC at room temperature. The combination of parameters, however, is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968.
  • Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or higher order DNA complexes.
  • the preparation of such probes and suitable hybridization conditions are well known in the art.
  • One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer.
  • a polynucleotide probe or primer used in the present invention may be labeled with any “reporter molecule,” so that it is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, chemical, and luminescent systems.
  • a polynucleotide probe or primer used in the present invention may further include a quencher moiety that, when placed very close to a label (e.g., a fluorescent label), causes there to be little or no signal from the label. It is not intended that the present invention be limited to any particular detection system or label.
  • the isolated polynucleotide of the invention is a primer that hybridizes, under highly stringent conditions, adjacent, upstream, or downstream to an alteration in DCDC2 that is associated with susceptibility for developing RD in humans.
  • a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to an alteration in the DCDC2 gene that is associated with susceptibility for developing RD.
  • primer refers to a polynucleotide that is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand is induced (i.e., in the presence of nucleotides, an inducing agent such as DNA polymerase, and suitable temperature, pH, and electrolyte concentration).
  • the primer may be capable of ligating to a proximal nucleic acid when placed under conditions in which ligation of two unlinked nucleic acids is induced (i.e., in the presence of a proximal nucleic acid, an inducing agent such as DNA ligase, and suitable temperature, pH, and electrolyte concentration).
  • a polynucleotide primer of the invention may be naturally occurring, as in a purified restriction digest, or may be produced synthetically.
  • the primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used.
  • the primer is an oligodeoxyribonucleotide. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.
  • the invention provides a pair of primers that specifically detect an alteration in the DCDC2 gene that is associated with susceptibility for developing RD.
  • the first primer hybridizes upstream from the alteration and a second primer hybridizes downstream from the alteration. It is understood that one of the primers hybridizes to one strand of a region of DNA that comprises an alteration in the DCDC2 gene that is associated with susceptibility for developing RD, and the second primer hybridizes to the complementary strand of a region of DNA that comprises an alteration in the DCDC2 gene that is associated with susceptibility for developing RD.
  • the term “region of DNA” refers to a sub-chromosomal length of DNA.
  • the invention provides a set of three primers useful for distinguishing between two alleles of DCDC2, wherein the first allele is a non-deleted DCDC2 gene and the second allele is a deletion in the DCDC2 gene that is associated with susceptibility for RD.
  • the first primer hybridizes to a nucleotide sequence that is common to both alleles, such as a non-allelic nucleotide sequence that is upstream or downstream of the polymorphic sequence in the DCDC2 gene.
  • a second primer specifically hybridizes to a nucleotide sequence that is unique to a first allele (e.g., a non-deleted DCDC2 gene).
  • a third primer specifically hybridizes to a nucleotide sequence that is unique to the second allele (e.g., a deletion in the DCDC2 gene that is associated with susceptibility for RD).
  • the set of three primers result in the amplification of a region of DNA that is dependent on which DCDC2 allele is present in the sample.
  • two primers out of the set may hybridize to a nucleotide sequence that is common to two alleles of the DCDC2 gene, such as non-allelic nucleotide sequences that are upstream and downstream of a polymorphic sequence in the DCDC2 gene, and a third primer specifically hybridizes to one of the two alleles of the DCDC2 gene.
  • the polynucleotides of the invention may be used in any assay that permits detection of a variation in the DCDC2 gene that is associated with susceptibility for developing RD. Such methods may encompass, for example, hybridization-mediated, ligation-mediated, or primer extension-mediated methods of detection. Furthermore, any combination of these methods may be utilized in the invention.
  • the polynucleotides of the invention detect an alteration in the DCDC2 gene that is associated with susceptibility for developing RD by amplifying a region of DNA that comprises the alteration. Any method of amplification may be used.
  • a region of DNA comprising the alteration is amplified by using polymerase chain reaction (PCR).
  • PCR in particular has become a research tool of major importance with applications in cloning, analysis of genetic expression, DNA sequencing, genetic mapping, drug discovery, and the like, e.g. Arnheim et al (Ann. Rev. Biochem., 61:131-156 (1992)); Gilliland et al, Proc. Natl. Acad.
  • PCR refers to the method of Mullis (See e.g., U.S. Pat. Nos. 4,683,195 4,683,202, and 4,965,188, herein incorporated by reference), which describes a method for increasing the concentration of a region of DNA, in a mixture of genomic DNA, without cloning or purification.
  • the polynucleotide primers of the invention are combined with a DNA mixture (or any polynucleotide sequence that can be amplified with the polynucleotide primers of the invention), wherein the DNA comprises the DCDC2 gene.
  • the mixture also includes the necessary amplification reagents (e.g., deoxyribonucleotide triphosphates, buffer, etc.) necessary for the thermal cycling reaction.
  • the mixture undergoes a series of denaturation, primer annealing, and polymerase extension steps to amplify the region of DNA that comprises the variation in the DCDC2 gene.
  • the length of the amplified region of DNA is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
  • hybridization of the primers may occur such that the ends of the primers proximal to the mutation are separated by 1 to 10,000 base pairs (e.g., 10 base pairs (bp) 50 bp, 200 bp, 500 bp, 1,000 bp, 2,500 bp, 5,000 bp, or 10,000 bp).
  • the invention described herein utilizes standard instrumentation for the amplification and detection of amplified DNA.
  • instrumentation has been developed for carrying out nucleic acid amplifications, particularly PCR, e.g. Johnson et al, U.S. Pat. No. 5,038,852 (computer-controlled thermal cycler); Wittwer et al, Nucleic Acids Research, 17: 4353-4357 (1989) (capillary tube PCR); Hallsby, U.S. Pat. No. 5,187,084 (air-based temperature control); Garner et al, Biotechniques, 14: 112-115 (1993) (high-throughput PCR in 864-well plates); Wilding et al, International application No.
  • PCT/US93/04039 PCR in micro-machined structures
  • Schnipelsky et al European patent application No. 90301061.9 (publ. No. 0381501 A2) (disposable, single use PCR device), and the like.
  • the invention described herein utilizes real-time PCR or other methods known in the art such as the Taqman assay.
  • the amplified DNA may be analyzed by several different methods. Such methods for analyzing the amplified DNA include sequencing of the DNA, determining the size of the fragment by electrophoresis or chromatography, hybridization with a labeled probe, hybridization to a DNA array or microarray, by incorporation of biotinylated primers followed by avidin-enzyme conjugate detection, or by incorporation of 32 P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment.
  • the amplified DNA is analyzed by gel electrophoresis. Methods of gel electrophoresis are well known in the art. See for example, Current Protocols in Molecular Biology, eds.
  • the amplified DNA can be visualized, for example, by fluorescent or radioactive means.
  • the DNA may also be transferred to a solid support such as a nitrocellulose membrane and subjected to Southern Blotting following gel electrophoresis.
  • the DNA is analyzed by electrophoresis and exposed to ethidium bromide and visualized under ultra-violet light.
  • the alteration in the DCDC2 gene that is associated with susceptibility for developing RD is a deletion.
  • the deletion may be detected using any of the polynucleotide primers described herein.
  • a set of three primers may be used to distinguish between an allele of the DCDC2 gene that comprises a deletion and a wildtype DCDC2 gene.
  • the set of three primers result in the amplification of a region of DNA that is dependent on which DCDC2 allele is present in the sample.
  • the amplified DNA is analyzed by DNA sequencing.
  • DNA sequence determination may be performed by standard methods such as dideoxy chain termination technology and gel-electrophoresis, or by other methods such as by pyrosequencing (Biotage AB, Uppsala, Sweden).
  • the nucleic acid sequence of the amplified DNA can be compared to the nucleic acid sequence of wild type DNA to identify whether a variation in the DCDC2 gene that is associated with susceptibility for developing RD is present.
  • the polynucleotides of the invention detect an alteration in the DCDC2 gene that is associated with susceptibility for developing RD by hybridization-mediated methods.
  • a polynucleotide probe hybridizes to an alteration in the DCDC2 gene, and flanking nucleotides, that is associated with susceptibility for developing RD, but not to a wild type CFH gene.
  • the polynucleotide probe may comprise nucleotides that are fluorescently, radioactively, or chemically labeled to facilitate detection of hybridization.
  • Hybridization may be performed and detected by standard methods known in the art, such as by Northern blotting, Southern blotting, fluorescent in situ hybridization (FISH), or by hybridization to polynucleotides on a solid support (e.g., DNA arrays, microarrays, cDNA arrays, or Affymetrix chips).
  • FISH fluorescent in situ hybridization
  • the polynucleotide probe is used to hybridize genomic DNA by FISH.
  • FISH can be used, for example, in metaphase cells, to detect a deletion in genomic DNA. Genomic DNA is denatured to separate the complimentary strands within the DNA double helix structure. The polynucleotide probe of the invention is then added to the denatured genomic DNA.
  • the probe will hybridize to the genomic DNA.
  • the probe signal e.g., fluorescence
  • the absence of signal indicates the absence of an alteration in the DCDC2 gene that is associated with susceptibility for developing RD. Presence of signal can also be used, in another embodiment, to determine the absence of an alteration in the DCDC2 gene.
  • the polynucleotides of the invention detect an alteration in the DCDC2 gene that is associated with susceptibility for developing RD by primer extension with DNA polymerase.
  • a polynucleotide primer of the invention hybridizes immediately adjacent to the alteration.
  • a single base sequencing reaction using labeled dideoxynucleotide terminators may be used to detect the alteration. The presence of an alteration will result in the incorporation of the labeled terminator, whereas the absence of an alteration will not result in the incorporation of the terminator.
  • a polynucleotide primer of the invention hybridizes to an alteration in the DCDC2 gene that is associated with the susceptibility for developing RD.
  • the primer, or a portion thereof, will not hybridize to a wild type DCDC2 gene.
  • the presence of an alteration will result in primer extension, whereas the absence of an alteration will not result in primer extension.
  • the primers and/or nucleotides may further include fluorescent, radioactive, or chemical probes.
  • a primer labeled by primer extension may be detected by measuring the intensity of the extension product, such as by gel electrophoresis, mass spectrometry, or any other method for detecting fluorescent, radioactive, or chemical labels.
  • the polynucleotides of the invention detect an alteration in the DCDC2 gene that is associated with susceptibility for developing RD by ligation.
  • a polynucleotide primer of the invention hybridizes to a variation in the DCDC2 gene that is associated with susceptibility for developing RD. The primer, or a portion thereof will not hybridize to a wild type DCDC2 gene.
  • a second polynucleotide that hybridizes to a region of the DCDC2 gene immediately adjacent to the first primer is also provided.
  • One, or both, of the polynucleotide primers may be fluorescently, radioactively, or chemically labeled.
  • Ligation of the two polynucleotide primers will occur in the presence of DNA ligase if an alteration in the DCDC2 gene that is associated with susceptibility for developing RD is present. Ligation may be detected by gel electrophoresis, mass spectrometry, or by measuring the intensity of fluorescent, radioactive, or chemical labels.
  • ORF Finder identifies two putative open reading frames (potential exons) within the deleted genomic sequence corresponding with 53 amino acids of putative open reading frame: MLIFLSPRGPHNLLICCNIKTDHRIKMANVSERFYLRTEEKCEEVDIVLSHS.
  • Deletions of the 2445 bases of genomic DNA from this region would also delete these amino acids.
  • this deletion is present in 17 of 108 severe dyslexics (15.7%, Table immediately below).
  • the control population reflects the frequency of dyslexia in the general population, reportedly 5 to 15%.
  • the deletion is present in 3 of 42 controls (7.1%).
  • the odds of developing dyslexia in a person with this deletion are twice that of a person without the deletion.
  • the PCR assay consists of three primers:
  • Applicants also developed a haplotype consisting of seven markers spanning DCDC2 that is associated with dyslexia:
  • DCDC2 rs2296539 A NCBI 24,397,408 25,522,804 Intron 5 rs2328208 G NCBI 24,393,548 25,412,218 Intron 5 rs807722 C NCBI 24,387,896 25,513,291 Intron 6
  • C_7454704_10 T
  • Celera 24,386,848 25,512,242 Intron 7 rs807700
  • Celera 24,381,770 25,507,166 Intron 7 rs793857 A NCBI 24,353,401 25,373,988 Intron 7
  • this haplotype is present in 15 of 63 severe dyslexics (23.8%, Table immediately below).
  • the control population reflects the frequency of dyslexia in the general population, reportedly 5 to 15%.
  • the haplotype is present in 3 of 36 controls (8.9%). The odds of developing dyslexia in a person with this haplotype are more than twice that of a person without the haplotype.
  • the haplotype assay consists of five custom markers from the NCBI dbEST database (rs2296539, rs2328208, rs807722, rs807700, rs793857) made exclusively for Applicants (Assay-by-Design®, ABI), and two proprietary markers (C — 7454704 — 10 and C — 7454731 — 10, Assay-on-Demand®, ABI/Celera).
  • FIG. 2 a Applicants constructed an intermarker linkage disequilibrium map ( FIG. 2 a ) spanning the 1.5 Mb with graphical overview of linkage disequilibrium (GOLD) and Haploview. There was evidence for five linkage disequilibrium blocks (A to E) spanning small clusters of SNPs in DCDC2 ( FIG. 2 b ). There were three blocks (F to H) centromeric of DCDC2 that corresponded to single marker QTDT peaks.
  • FIG. 3 is a graphic presentation of the haplotype transmission disequilibrium data, which is also provided in tabular form in Supplementary Tables 2a and 2b.
  • a haplotype in each of blocks A, C, D, E, F, and G was associated with compromised performance in several reading tasks in the context of preserved IQ.
  • Haplotype blocks A, C, D, and E were located in DCDC2. There were no haplotypes in block H that showed significant association with any of the cognitive phenotypes.
  • STR polymorphic compound STR (dbSTS ID 808238) comprised of 11 alleles containing variable copy numbers of (GAGAGGAAGGAAA) n and (GGAA) n repeat units (Supplementary Table 3).
  • CLDRC polymorphic compound STR
  • some alleles were present only in the parents (five) and others—including the deletion—occurred too infrequently in probands to compute transmission disequilibrium.
  • TESS (24) comparison to the TRANSFAC database identified 131 putative transcription factor binding sites distributed through the 168 bp of the purine-rich region, including four copies each of PEA3 (AGGAAA) and NF-ATp (AGGAAAG) sites in repeat unit 1 of dbSTS ID 808238. Both transcription factors are expressed in mouse brain.
  • PEA3 is associated with sexual function and peripheral motor neuron arborization (25).
  • NF-ATp mediates rapid embryonic axon extension necessary for forming neuronal connections (26), which would complement the putative function of the doublecortin peptide domains in DCDC2.
  • FIG. 4 shows the expression levels of eight genes in 17 regions of human brain normalized to thalamus by quantitative real time RT-PCR; thalamus is a region of the brain that has not consistently been implicated in reading.
  • the most variably expressed genes were KIAA0319, MRS2L, and DCDC2.
  • KIAA0319 was most highly expressed in the superior parietal cortex, primary visual cortex, and occipital cortex.
  • MRS2L was most highly expressed in the superior temporal cortex, hypothalamus, and amygdala.
  • DCDC2 was most highly expressed in the entorhinal cortex, inferior temporal cortex, medial temporal cortex, hypothalamus, amygdala, and hippocampus.
  • Expression of TTRAP, THEM2, Geminin, and ALDH5A in the 17 regions of the brain did not differ significantly from thalamus.
  • RNAi was used to test for a functional role of DCDC2 in neuronal migration.
  • Co-transfection of plasmid vectors encoding shRNA targeted against DCDC2 sequence in developing neocortex or control scrabbled sequence along with an eGFP expression plasmid was performed at gestational day 14 in the rat.
  • This transfection method initially labeled approximately 1% of cells at the surface of the ventricles where new neurons undergo their terminal mitoses. Cells migrate from this surface to the pial surface in four to six days. We assessed the progress in migration four days following transfection for the two conditions. As shown in FIG.
  • GRUENLAB REFERENCE SEQUENCE SOURCE Gruenlab reference sequence compiled from ABI files generated Jan. 10, 2005 through Jan. 21, 2005, from a single sub-clone of genomic DNA from a single subject, NA10848 (CEPH Family 1332). NA10848 DNA was purchased from the Coriel Institute (Camden, NJ).
  • ANNOTATIONS Location: Intron 2 of DCDC2 (MIM:605755) Length: 2,837 bases in length
  • Direction: pter to cen on 6p Base #1 corresponds to base number 21,571 in clone RP11-95P3 in the NCBI database (http://www.ncbi.nlm.nih.gov/).
  • Base #1 corresponds to base number 24,433,259 in ENSEMBL v33-September 2005 (http://wxvw.ensembl.org/Multi/blastview).
  • Deletion breakpoints between base #87-88 (pter) between base #2,532-2,533 (cen) Flanking sequence: base 1 through base 87 (pter) base 2,533 through base 2,837 (cen) Deletion range: 2,445 bases
  • the 170basepair purine-rich region in intron 2 of DCDC2 (starting at 24,434,282, ENSEMBL database version 33 Sep. 2005), is a very unique sequence comprised of nearly G and A bases exclusively.
  • TESS (24) comparison to the TRANSFAC database identified 131 putative transcription factor binding sites distributed through this region, including four copies each of PEA3 (AGGAAA) and NF-ATp (AGGAAAG) sites in dbSTS ID 808238 (Table 3). Both transcription factors are expressed in mouse brain.
  • PEA3 is associated with sexual function and peripheral motor neuron arborization (25).
  • NF-ATp mediates rapid embryonic axon extension necessary for forming neuronal connections (26), which would complement the putative function of the doublecortin peptide domains in DCDC2.
  • the presence of these binding sites suggests that the purine-rich region likely functions as an enhancer or regulatory region that could modify DCDC2 expression in terms of tissue or cell specificity, developmental timing, or quantity.
  • this region can actually bind transcription factor proteins, short double-stranded oligonucleotide probes, EMSA1, EMSA2, EMSA3, and EMSA4 (positions shown in figure below), were synthesized from the sequence of the purine rich region and tested for protein binding using the electrophoretic mobility shift assay:
  • the polymorphisms of the purine-rich region—including the 2,445base deletion—could act by disrupting or modifying DNA-protein interactions, and the specific DCDC2 enhancer-regulatory function encoded in this intron.
  • the result would be a profound effect on DCDC2 expression, which, as shown by the RNAi data (Example 9), would have a significant effect on neuronal migration and ultimately reading ability.
  • DCDC2 (also called RU2 and KIAA1154, MIM: 605755) is located in the DYX2 locus 500 kb from JA04. The function is unknown but it contains two doublecortin peptide domains that were originally described in the doublecortin gene (DCX, MIM: 300121) encoded on the X chromosome.
  • DCX encodes a cytoplasmic protein that directs neuronal migration by regulating the organization and stability of microtubules, and is mutated in human X-linked lissencephaly (27) and double cortex syndrome. Lissencephaly is a neuronal migration defect that produces profound mental retardation and seizures (28).
  • Double cortex syndrome is caused by arrested migration halfway to the cortex producing a subcortical neuronal band heterotopia or “double cortex.” For both syndromes the large majority of point mutations cluster within the conserved doublecortin peptide motifs of DCX, which are also encoded in DCDC2.
  • Converging imaging data implicate three important regions in the left hemisphere that are important for fluent reading: the anterior system in the inferior frontal region, the dorsal parietotemporal system involving the angular, supramarginal, and posterior portions of the superior temporal gyri, and the ventral occipitotemporal system involving portions of the middle temporal and middle occipital gyri (3, 29).
  • Imaging studies of dyslexic adults and children show a disruption of posterior reading systems in parieto-temporal and occipito-temporal regions (30).
  • DCDC2 is highly expressed in the same regions activated by fluent and dyslexic readers, suggesting that dysregulation—attributable to polymorphisms of a regulatory region—and not complete disruption of a protein product participating in axonal guidance and growth, could explain the expression patterns.
  • DCDC2 alleles that associate with dyslexia would not be expected to be nulls, and so even if DCX and DCDC2 had similarly critical roles in neuronal migration, large malformations would not be an expected phenotype for the described alleles.
  • RNAi results following DCX RNAi (32) suggest that DCX may be necessary for neuronal migration while DCDC2 may be more modulatory.
  • DCDC2 RNAi treatment allows cells to migrate farther, attain typical migratory bipolar morphologies, and does not induce the formation of large sub-cortical band heterotopia.
  • RNAi treatment does not exclusively target neurons that populate reading centers, when considered in the context of DCDC2 expression in inferior and medial temporal cortex, it offers a plausible pathophysiologic mechanism for RD due to genetic expression heterogeneity.
  • DCDC2 heterogeneity is also consistent with other pathophysiologic mechanisms. Imaging studies have shown a functional disruption of a more subtle nature—demonstrable only in composite maps of pooled subjects imaged at 1.5 tesla—in areas where heterotopias have not been described. Accordingly, it may be that DCDC2 heterogeneity sensitizes the dyslexic reader to disruption in the development of “a hierarchy of local combination detectors” in the occipito-temporal system, as postulated most recently by Dehaene and colleagues (33).
  • KIAA0319 is a reasonable candidate, but the reported paucity of polymorphisms in disequilibrium with reading phenotypes (35)—confirmed by sequencing in the CLDRC cohort—made it less attractive. Furthermore, in Applicants' population, transmission disequilibrium was mostly from short haplotypes confined to DCDC2 (blocks A through E), with minimal support for association from single markers within MRS2L, GPLD1, KIAA0319, TTRAP, and THEM2 (Supplementary Table 1). Block F, spanning GPLD1 just telomeric of DCDC2, also has one haplotype in disequilibrium.
  • No other haplotypes spanning GPLD1 show significant disequilibrium (data not shown).
  • the origin of the transmission disequilibrium from block G is unknown and it spans no recognizable coding sequences. Although it is located within 118 kb of a published peak in THEM2, Applicants found no disequilibrium with any Haploview block on either side of block G or spanning THEM2 (35).
  • RD is a complex phenotype and several, if not many, genes are involved. Since they are often functionally grouped on chromosomes, it is possible that variations within more than one gene on 6p22 are responsible for interindividual differences in RD, which may be apparent in further studies of additional populations.
  • the 536 samples (parents and siblings) consisted of 153 nuclear families collected by the Colorado Learning Disabilities Research Center (CLDRC) (37). Subjects included members of MZ twin pairs (in which case, only one member of the MZ twin pair was used), DZ twin pairs, and nontwin siblings. There were 34 families with one offspring, 94 families with two offspring, 19 families with three offspring, and 6 families with four or five offspring. Predominantly white middle-class families were ascertained from school districts in the state of Colorado, where at least one sibling had a school history of reading problems. Subjects with IQ less than 80 or for whom English was a second language were not included in the initial sample.
  • Phonological decoding is the oral reading of nonwords, which have straightforward pronunciations that are based on their spelling.
  • Phonemic awareness is the ability to isolate and manipulate abstract subsyllabic sounds in speech; for the present analyses, it was measured with an experimental phoneme-transposition (PTP) and phoneme-deletion (PDL) tasks, as well as with a composite score for both tests.
  • WR was measured with an experimental timed-word-recognition (TWR) task and the untimed standardized PIAT word-recognition (PWR) task, which required subjects to read words aloud; a composite score for both tests was also created.
  • the discriminant score (DISC) for reading was a weighted composite of the reading recognition, reading comprehension, and spelling subtests of the PIAT. These psychometric tasks have been described in detail elsewhere (17, 23, 37-39).
  • the population average was estimated from the large twin database available at the CLDRC. After age regression and standardization, the phenotypic data for each of the reading tasks formed a continuous distribution of quantitative z scores, which were used in the analyses.
  • RNA samples from 18 areas of adult human brain were purchased from Ambion (see FIG. 4 ), and were procured from 10 white donors ranging in age from 45 to 79 years, with unknown handedness. RNA samples could not be localized to either the left or right hemispheres. Six donors were male. Seven donors died due to cardiac (e.g. congestive heart failure) or respiratory disease (e.g. respiratory failure), one had liver cancer, one had bladder cancer, and one was listed as unknown.
  • cardiac e.g. congestive heart failure
  • respiratory disease e.g. respiratory failure
  • TaqMan Assay-on-Demand® and Assay-by-Design® probes were used to genotype 109 and 39 SNPs respectively.
  • the common 2,445 bp deletion was genotyped by allele-specific amplification with a combination of three primers in one reaction: universal forward primer (AGCCTGCCTACCACAGAGAA), reverse primer for non-deleted chromosomes (GGAACAACCTCACAGAAATGG), and reverse primer for deleted chromosomes (TGAAACCCCGTCTCTACTGAA). Reaction products were resolved on 1.5% agarose gels. The deletion fusion fragment was 176 bp and the non-deleted fragment was 486 bp.
  • the compound STR was genotyped by sequencing PCR products generated with forward primer (TGTTGAATCCCAGACCACAA) and reverse primer (ATCCCGATGAAATGAAAAGG). The sequencing method is described below. Sequence traces results were analyzed and alleles assigned with Mutation Surveyor version 2.6 (SoftGenetics, State College), by comparing samples to reference traces after alignment.
  • DNA samples were formatted into two 384-well plates with at least one negative control (no genomic DNA) and two positive controls (CEPH NA10848 and NA10849, Coriell Institute, Camden) in each quadrant of 384-well plates. Genetic analyses were only performed on data from plates where the negative control showed negative results, and positive controls showed identical genotypes. Two STR markers from the pseudo-autosomal regions of the sex chromosomes were genotyped to check the sex ID of samples. Data were preprocessed to remove genotype combinations that resulted in Mendelian incompatibilities, low-quality DNA samples, and to detect any pedigree errors. Lastly, all markers with extreme amounts of missing data were removed, to exclude loci where genotyping might have been problematic.
  • PCR was used to generate 68 amplicons from 26 RD and 6 normal genomic DNA samples from RD sample set 1 for DCDC2, MRS2L, and KIAA0319. Upon completion of thermal cycling, the PCR products were treated with ExoSAP-IT (USB, Cleveland, Ohio) to remove residual dNTPs and primers. DNA sequencing was performed in both forward and reverse directions with Big Dye (ABI) fluorescently labeled dideoxy terminator and the reaction products were resolved by capillary electrophoresis and laser detection on a 3730XL Automated DNA Sequencer (ABI). Sequence alignments and comparisons were made using Phred, Phrap, Polyphred, Consed, and Mutation Surveyor (SoftGenetics, State College, Pa.).
  • TaqMan gene expression kits for eight genes in the candidate region (KIAA0319, DCDC2, MRS2L, GPLD1, ALDH5A1, TTRAP, HT012, and GMNN) and six control genes (GAPDH, 18S, ⁇ actin, HPRT1, PPIA and PKG1) were purchased from ABI.
  • RNA samples were reverse transcribed to cDNA with the High Capacity cDNA Archive Kit (ABI). Then real time PCR was performed with the default SDS condition on the 7900HT (ABI). Each sample was tested in triplicate.
  • RNA templates were subjected to a sham reverse transcription step with random primers and without RT enzyme, followed by PCR with primers from three of the control genes.
  • six genes, GAPDH, 18S, P actin, HPRT1, PPIA and PKG1 were tested for consistent expression in all 18 brain samples.
  • To compare RT-PCR efficiencies relative standard expression curves for the eight 6p22 and six control genes were generated. It demonstrated that efficiencies of target and reference are approximately equal.
  • the comparative C T method which normalizes expression to an endogenous reference and a calibrator, was used for quantitative relative gene expression.
  • Plasmids were directly introduced into cells at the cerebral ventricular zone of living rat embryos by in utero electroporation as previously described (32). Cells were co-transfected with pCA-eGFP and DCDC2 shRNA plasmid or control shRNA plasmid.
  • the shRNA plasmid directed against DCDC2 contained the hairpin sequence 5′ cccaccaagcaattccagacaa(aca)ttgtctggaattgcttggtggg 3′ and the control sequence was 5′ cccagtcaaggcattgaattaaa(aca)tttaattcaatgccttgactggg 3′.
  • the sequence was selected by its asymmetry and for absence of any matches to rat genomic sequence in the database.
  • Four days after transfection rat embryonic brains were fixed with 4% paraformaldehyde and sectioned with a vibratome (Leica VT1000S) at 60 ⁇ 80 ⁇ m. eGFP fluorescence was observed nuclei were labeled with TOP-PRO-3 (Molecular Probes). Images were acquired with a Leica TCS SP2 confocal microscope system (0.5 ⁇ 1.0 um optical section) and processed using Photoshop 7.0. For cumulative probability migration plots the distance of each cell (200-1400 in each analysis condition) from the VZ surface was determined 4 days after transfection. Migration distances were determined with automated particle analyses in ImageJ (Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, Md., USA).
  • the marker density was 8.7 kb per SNP. Minor allele frequencies were greater than 5% for cSNPs and greater than 15% of all others.
  • TaqMan PCR plates in 384-well configuration were formatted with the Hydra II plus-one liquid handling system (Matrix Technologies, Hudson, N.H.). Reaction volumes were 2 ⁇ l with 1.6 ng of template DNA and TaqMan Universal Master Mix without uracil-DNA-glycosylase (ABI). Plates were cycled in the PE 9700 (ABI): initial denaturation step of 10 min at 95° C., followed by 40 cycles of 15 sec at 95° C. and 1 min at 60° C. Fluorescent signals were collected on the 7900HT (ABI) and converted to genotype data by the Sequence Detection System (SDS, ABI).
  • SDS Sequence Detection System
  • a total of 20 ⁇ l PCR reaction contained 10 ng of genomic DNA, 0.4 units Hotstart Taq polymerase (Qiagen), 4 pmoles of forward PCR primer, 0.4 pmoles of reverse PCR primer (5′-T3 tag), 3.6 pmoles of biotinylated T3 primer, 2.5 mM MgCl 2 , and 200 ⁇ M dNTPs.
  • Thermal cycling conditions were 15 min at 95° C., following by 45 cycles (30 sec at 95° C., 45 sec at 56° C., 60 sec at 72° C.), 5 min at 72° C., and a hold at 4° C.
  • biotinylated PCR product from the entire reaction was purified by binding to streptavidin-sepharose (Amersham) using the Filter Prep tool according to the standard protocol provided by Pyrosequencing, Inc.
  • the Pyrosequencer software automatically scored each reaction and assigned genotypes.
  • MRS3 changed the start codon from ATG to ATC.
  • the minor alleles of MRS1(A), MRS3(C), MRS4(G), MRS5(T), and MRS6(T) were transmitted only once in the RD cohort. All nine SNPs in MRS2L were genotyped in the RD families by fluorescent dideoxy sequencing or pyrosequencing.
  • C6orf62 is a predicted gene in Ensembl database (Vega), and is equivalent to KIAA0385 in NCB1 and Celera.
  • DISC Discriminant Score
  • PTP Phoneme Trasposition
  • TWR Timed Word Recognition
  • PWR PIAT Word Recognition
  • WR Word Recognition Composite
  • PD Phonological Decoding
  • OCH Orthographic Choice
  • HCH Homonym Choice
  • OC Orthographic Choice + Homonym Choice
  • PA Phoneme Transposition + Phoneme Deletion : cSNPs that change the amino acid sequence of the corresponding protein.
  • Single marker TDT peaks with p ⁇ 0.01. : Minor allele frequency in populations other than Caucasian in the Celera database.
  • Haplo- type Fre- Haplotype Block ID
  • Haplotype quency A 5 markers 1 A A A G G 0.60 SNP ID: 21, 22, 23, 24, and 25 2 G C G G G 0.25 spanning 6523 bp in Ensembl 3 A A G A T 0.07 B 2 markers 1 G C 0.63 SNP ID: 26 and 27 2 A T 0.21 spanning 17287.5 bp in Ensembl 3 G T 0.15 C 8 markers 1 G T G A G A T G 0.62 SNP ID: 32, 33, 34, 35, 36, 37, 2 A T C G A T T C 0.12 38, and 39 3 G T G A G A T C 0.06 spanning 33631 bp in Ensembl 4 A C C A A T T A 0.06 5 A C C G A T A A 0.05 D 5 markers 1 G G G A G 0.54 SNP ID: 42, 43, 44, 45, and 46 2 C G A T A 0.15 spanning 11472 bp in Ensembl 3 C A

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US11/662,325 2004-09-14 2005-09-14 Identification of Gene Associated with Reading Disability and Uses Therefor Abandoned US20080318217A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/662,325 US20080318217A1 (en) 2004-09-14 2005-09-14 Identification of Gene Associated with Reading Disability and Uses Therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61002304P 2004-09-14 2004-09-14
US68510105P 2005-05-26 2005-05-26
PCT/US2005/033114 WO2006032021A2 (fr) 2004-09-14 2005-09-14 Identification de gene associe a deficience de lecture et ses utilisation
US11/662,325 US20080318217A1 (en) 2004-09-14 2005-09-14 Identification of Gene Associated with Reading Disability and Uses Therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033114 A-371-Of-International WO2006032021A2 (fr) 2004-09-14 2005-09-14 Identification de gene associe a deficience de lecture et ses utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/967,291 Continuation US9828639B2 (en) 2004-09-14 2013-08-14 Identification of gene associated with reading disability and uses therefor

Publications (1)

Publication Number Publication Date
US20080318217A1 true US20080318217A1 (en) 2008-12-25

Family

ID=36060726

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/662,325 Abandoned US20080318217A1 (en) 2004-09-14 2005-09-14 Identification of Gene Associated with Reading Disability and Uses Therefor
US13/967,291 Active US9828639B2 (en) 2004-09-14 2013-08-14 Identification of gene associated with reading disability and uses therefor
US15/805,095 Abandoned US20180119224A1 (en) 2004-09-14 2017-11-06 Identification of gene associated with reading disability and uses therefor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/967,291 Active US9828639B2 (en) 2004-09-14 2013-08-14 Identification of gene associated with reading disability and uses therefor
US15/805,095 Abandoned US20180119224A1 (en) 2004-09-14 2017-11-06 Identification of gene associated with reading disability and uses therefor

Country Status (2)

Country Link
US (3) US20080318217A1 (fr)
WO (1) WO2006032021A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504761A (zh) * 2018-12-12 2019-03-22 复旦大学 检测女性原发不孕的panx1基因及检测该基因突变的试剂盒
US11155871B2 (en) * 2012-11-07 2021-10-26 Yale University Assessing risk of reading and language impairment

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017218522B3 (de) 2017-10-17 2018-12-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur genbasierten Diagnose eines Legasthenierisikos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525467A (en) * 1991-06-13 1996-06-11 Imperial Chemical Industries Plc Nucleotide sequences
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US20030118998A1 (en) * 2001-10-15 2003-06-26 Dean Frank B. Nucleic acid amplification
US7355022B2 (en) * 2002-02-12 2008-04-08 Licentia Ltd. Gene functionally related to dyslexia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2917369B1 (fr) 2012-11-07 2019-01-09 Yale University Estimation du risque d'une déficience de la lecture et du langage

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525467A (en) * 1991-06-13 1996-06-11 Imperial Chemical Industries Plc Nucleotide sequences
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US20030118998A1 (en) * 2001-10-15 2003-06-26 Dean Frank B. Nucleic acid amplification
US7355022B2 (en) * 2002-02-12 2008-04-08 Licentia Ltd. Gene functionally related to dyslexia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155871B2 (en) * 2012-11-07 2021-10-26 Yale University Assessing risk of reading and language impairment
CN109504761A (zh) * 2018-12-12 2019-03-22 复旦大学 检测女性原发不孕的panx1基因及检测该基因突变的试剂盒

Also Published As

Publication number Publication date
US20180119224A1 (en) 2018-05-03
US9828639B2 (en) 2017-11-28
WO2006032021A2 (fr) 2006-03-23
WO2006032021A3 (fr) 2007-02-15
US20140051076A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
US20060068428A1 (en) Identification of genetic markers associated with parkinson disease
US11214834B2 (en) Methods of detecting Charcot-Marie tooth disease type 2A
US8206911B2 (en) Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same
US20180119224A1 (en) Identification of gene associated with reading disability and uses therefor
JP2007527241A (ja) 上皮細胞成長因子受容体遺伝子プロモーターにおける多型
BR112016022582B1 (pt) Marcadores mitocondriais de doenças neurodegenerativas
US20090176878A1 (en) Genetic polymorphisms and substance dependence
US20220349008A1 (en) Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same
JP7199106B2 (ja) 被験者における興奮性亢進の判定方法及びキット
US20030032099A1 (en) Methods for predicting susceptibility to obesity and obesity-associated health problems
CA2627289A1 (fr) Variantes genetiques de polyphosphate-4-phosphatase inositol humain, de type i (inpp4a) servant a la prediction et la therapie de troubles immunologiques
US7709204B2 (en) Assessing brain aneurysms
EP2141250A1 (fr) Procédé de diagnostic et de prédiction d'ataxie cérébelleuse
WO2015016392A1 (fr) Nouveau gène responsable de la sclérose latérale amyotrophique
US8124337B2 (en) Hereditary cataract status in canines based on HSF4 gene marker
WO2004029290A2 (fr) Haplotype de susceptibilite a la maladie de parkinson utilise comme un outil pour le criblage genetique
US9752195B2 (en) TTC8 as prognostic gene for progressive retinal atrophy in dogs
KR20110011306A (ko) 텔로미어 유지 유전자를 이용한 폐암 감수성 진단용 마커 및 폐암 감수성 예측 및 판단 방법
JP4998874B2 (ja) 炎症性疾患の判定方法
US20110143344A1 (en) Genetic polymorphisms and substance dependence
Mensah et al. Molecular analysis of a chromosome 4 inversion segregating in a large schizophrenia kindred from Hong Kong
Glanzmann An investigation into the molecular aetiology of Parkinson's disease in South African patients

Legal Events

Date Code Title Description
AS Assignment

Owner name: YALE UNIVERSITY, CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRUEN, JEFFREY R.;MENG, HAIYING;REEL/FRAME:020816/0329;SIGNING DATES FROM 20080313 TO 20080331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION